NBIO News and Press, Nascent Biotech From 01/18/23

Markets are starting to perk up in 2023 after a long and difficult bear market year in 2022. Investors eager to put capital back to […] For further details see: NBIO Fits Profile for Strategy Targeting Early Stage Biotech

NORTH PALM BEACH, FL / ACCESSWIRE / January 10, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting various cancer types, announced today the completion an...

VERO BEACH, FL / ACCESSWIRE / December 20, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting the treatment of various cancers, announced today that Dr. Ivan Babic, a renown...

With the Biotechnology space rotating toward a more acquisition friendly dynamic, investors may benefit from a studied focus on likely takeout candidates – particularly early-stage […] For further details see: Fishing for Bargains… Nascent Biotech (OTCMKTS:NBIO) Ripe fo...

Nascent Biotech Inc. (OTCMKTS:NBIO) is an emerging player in the $4 billion oncology drug development space. NBIO is early-stage – its flagship drug is just heading toward Phase 2 clinical research – which is in the sweet spot for dealmaking as a potential acquisition target as ...

Nascent Biotech ( OTCQB:NBIO ) said the U.S. Patent and Trademark Office (USPTO) will issue a patent covering claims related to the monoclonal antibody pritumumab. The U.S. patent No. 11,492,394, titled 'Kits and containers for treating vimentin expressing tumors...

VERO BEACH, FL / ACCESSWIRE / November 1, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company who develops monoclonal antibodies targeting treatment of various cancers, announced today that the United States Paten...

Nascent Biotech Inc. (OTCMKTS:NBIO) is an interesting name in the oncology treatment space. The company is in the very final phases of its first phase 1 trial process, with encouraging updates throughout the process. With Biotechs now outperforming the major indices, early-stage pipeline oppo...

The Biotechnology space has been hammered this year along with growth technology stocks as fund managers follow the historical playbook on rising rates – higher risk-free returns from fixed income instruments pulls investor duration forward, which means money flows from stocks that hav...

Shares of OTC listed Nascent Biotech ( OTCQB:NBIO ) fell 16.1% to $0.26 in Tuesday morning trading, continuing a recent weak trend for the stock which has seen it post losses in six of its last seven sessions . NBIO shares posted a five-day losing streak last week, includi...